The gut microbiota plays important roles in nutrient absorption, immune system development, and pathogen colonization resistance. Perturbations early in life may be detrimental to host health in the short and the long-term. Antibiotics are among the many factors that influence the development of the microbiota. Because antibiotics are heavily administered during the first critical years of gut microbiota development, it is important to understand the effects of these interventions. Infants, particularly those born prematurely, represent an interesting population because they receive early and often extensive antibiotic therapy in the first months after birth.
Introduction
The infant gut microbiota is shaped by both prenatal and postnatal factors. 1, 2 Following birth, the infant gut microbiota undergoes a patterned maturation process. [3] [4] [5] This process begins with a few taxa, but this population inexorably expands in content and concentration until it approaches an adultlike microbial configuration dominated by Bacteroidetes and Firmicutes. 3, [6] [7] [8] Perturbation of the gut microbiota during this key developmental window can have lasting effects on host physiology and disease risk. [9] [10] [11] [12] [13] [14] One of the most common perturbations during this period, antibiotic therapy, 13, 15 can substantially alter the gut microbiota and infant physiology. 10, [16] [17] [18] [19] [20] [21] Because preterm infants are at high risk for infection, antibiotics are the most commonly prescribed medications in neonatal intensive care units (NICUs) in the United States ( Fig. 1 ) 15, 22, 23 accounting for 3 of the top 6 medications with the greatest relative increase in use in NICUs in the United States between 2005 and 2010. 24 Antibiotic-induced gut microbiota dysbioses in this population have been linked to the pathogenesis of necrotizing enterocolitis, [25] [26] [27] late onset sepsis, 28, 29 and other adverse health outcomes. 30 While these correlations exist, the underlying etiologies remain unclear, motivating the study of microbiota development in the context of antibiotic therapy in this vulnerable population that accounts for nearly 10% of all births in the United States.
Techniques for studying development of the infant gut microbiota and the developing resistome Microbial ecology studies, especially those focused on the gut microbiota, have flourished because of widespread adoption of sequencing-based studies, either using the 16s rRNA gene or metagenomic shotgun sequencing, resulting in a deeper appreciation of microbiome diversity. 4, 20, 27, [32] [33] [34] Until recently, similar efforts to characterize the preterm infant gut reservoir of antibiotic resistance genes (the resistome) have been largely culture or PCR-based. While these methods can provide a high level overview of the resistome, they underestimate diversity, are limited to previously known resistance genes, and are only semi-quantitative. In contrast, deep sequencing of microbiomes paired with functional metagenomics offers an unbiased method to identify functional resistance determinants in stool, and can provide quantitative information on microbiome and resistome architecture. 35, 36 Gibson et al. recently used this suite of techniques to develop a sequence-unbiased account of the effects of antibiotic therapy on the preterm infant microbiota with respect to phylogeny and antibiotic resistance gene distribution. 37 A longitudinal, sequencing based interrogation of the preterm infant gut microbiota
To assess the effects of antibiotics on the dynamics of the preterm infant gut microbiota, Gibson et al.
assembled a cohort consisting of 84 preterm infants, of whom 82 received antibiotics within the first 24 to 48 hours of life, as is common practice in the NICU. However, 39% received no further antibiotic therapies after the first week of life, allowing them to serve as controls to study the effects of antibiotic treatment on preterm infants in the first weeks of life. All infants in the cohort were low birthweight and born prematurely, with a median gestational age of 27 weeks and a median birthweight of 865 g. This sample set was complemented by robust metadata including detailed histories of all antibiotic exposures, overall health indications including infections, delivery mode, postmenstrual age, hospital environment, enteral feeding, other medications, and maternal health.
A total of 401 stools from these infants, collected longitudinally during their stay in the NICU and ranging from day 6 to day 158 of life, were interrogated by shotgun metagenomic sequencing. In total, Gibson et al. sequenced and analyzed 551 gigabases (Gb) of preterm infant gut metagenomes (1.37 C/¡ 1.17 Gb per sample) and a total of 107 Gb of functionally selected preterm infant resistomes (5.1 C/¡ 3.6 Gb per sample). Unique clade-specific marker genes from approximately 17,000 reference genomes were used to assess the phylogenetic composition allowing both species-level resolution and accurate relative abundance estimations of bacterial species composition of these communities, an advantage over traditional 16S rRNA marker gene sequencing. 38, 39 This represents the largest metagenomic sequencing-based study of the preterm infant gut microbiota to date, providing the statistical power to address questions of microbiota and resistome development in preterm infant populations subject to heavy antibiotic exposure.
Antibiotics disrupt the preterm gut microbiota richness and composition
Gut microbial species richness, defined as the number of species present in a microbiota, is widely used as a measure of microbiome health. Decreased species richness in infancy has been associated with a number of host pathologies. 13, 25, 40, 41 To identify factors that significantly contribute to species richness, Gibson et al. developed a generalized linear mixed model with individual included as a random effect, leveraging available metadata including infant health (e.g. CRIB II (Clinical Risk Index for Babies) score, day of life, gestational age, birthweight, delivery mode, and presence of positive culture), medications (e.g., antibiotics, caffeine, and iron), and maternal health (e.g. preeclampsia and premature membrane rupture). While postmenstrual age and breast milk significantly contribute to increased species richness, the opposite was true with high CRIB II score, meropenem treatment, cefotaxime treatment, and ticarcillin-clavulanate treatment significantly contributing to decreased species richness. Cumulative antibiotic exposure in infants was associated with a significant reduction in species richness and, with the exception of gentamicin, all antibiotics were associated with reduced species richness. This decrease in species richness occurred over intervals during which the gut microbiota of agematched, antibiotic-na€ ıve preterm infants was increasing in richness, and was accompanied by disruption of microbiota composition ( Fig. 2A-C) . For example, one individual had a »25% decrease in observed species following meropenem treatment, while over the same period a matched control had a 20% increase ( Fig. 2A) . Similar age-matched comparisons can be made for combined vancomycin and meropenem treatment (Fig. 2B ) and for ticarcillin-clavulanate treatment (Fig. 2C) . Antibiotic-induced perturbations of microbiota phylogenetic composition were observed for these infants as well ( Fig. 2A-C) . 35, 42 These libraries, representing a total of 107 Gb of bacterial DNA, were screened against 16 antibiotics, including those routinely used in NICUs. Of the 794 functionally identified antibiotic resistance genes, 42% were encoded by E. coli, Enterobacter cloacae, and K. pneumoniae, taxa which include many pathogenic strains implicated in nosocomial infections in preterm infants. 34, 43 Interestingly, the sequences of the majority of resistance determinants uncovered by the functional metagenomics screens were already present in protein databases. However, they were not found in antibiotic resistance specific databases, indicating that they had not previously been ascribed a resistance function and highlighting a key advantage of using functional metagenomics.
Antibiotic therapy enriches
One third of the antibiotic resistance genes identified by functional selections conferred resistance to multiple antibiotics, often across classes, or were coselected with another antibiotic resistance gene. For example, the loci selected by piperacillin also conferred resistance to other b-lactam antibiotics. In fact, many b-lactamases identified in this study conferred resistance to multiple classes of b-lactam antibiotics. In addition to these genes, which may be extended spectrum b-lactamases (ESBLs), Gibson et. al. identified multiple Ambler class A b-lactamases, and b-lactamases that conferred resistance to both penicillins and 2 nd and 3 rd generation cephalosporins. ESBLs are of particular concern due to their increasing abundance in community acquired infections and in clinical settings such as the NICU, often in Enterobacteriaceae family members, including those that Gibson et. al. identified as dominant members of the preterm infant gut microbiota. 44 In addition to cross resistance among b-lactam antibiotics, Gibson et. al. also observed contigs that conferred resistance across classes of antibiotic. For example, many tetracycline resistance contigs also conferred resistance to both chloramphenicol and cefoxitin. Our findings suggests that many of these genes may be present in the context of a multidrug drug resistance cassette and are threats for dissemination via horizontal gene transfer. Multidrug-resistance is one of 2 key features associated with spread of antimicrobial resistance in the preterm infant gut microbiota. The other feature is mobility, or the likelihood of horizontal gene transfer. In order to investigate the potential mobility of resistance genes in the preterm infant gut microbiome Gibson et al. assembled metagenomic contigs from shotgun reads, and found widespread plasmid and chromosomally encoded multidrug resistance clusters. Alarmingly, the authors identified plasmid-associated antibiotic resistance genes encoding resistance to more than 6 antibiotic classes in 96% of preterm infant gut samples. Furthermore, the preterm infant resistome was found to be highly resilient. Over the course of time represented by the longitudinally sampled resistome, only about one fifth of the resistance gene classes showed significant change, implying that early life antibiotic therapy may select for a lasting expansion of the gut resistome.
The predictable response of the preterm infant gut microbiota to antibiotic therapy
To quantify changes to the gut microbiota before and after antibiotic treatment Gibson et al. utilized metagenomic shotgun sequencing to interrogate the phylogenetic architecture of the bacterial community. While meropenem, cefotaxime, and ticarcillin-clavulanate each significantly and immediately reduced species richness, gentamicin and vancomycin (2 of the most commonly used antibiotics in preterm infant populations, and which are often co-administered) resulted in variable species richness responses. Using random forests classification, the direction of species richness response to vancomycin and gentamicin treatment can be predicted based on the relative abundance of only 2 species (Staphylococcus aureus and E. coli) and 2 antibiotic resistance genes (cpxR and cpxA) with an error rate of only 15%. We hypothesize that this finding might be due to the innate vancomycinresistance of Gram-negative bacteria such as E. coli and the innate vancomycin-susceptibility of S. aureus, coupled with the ability of cpxR and cpxA to confer gentamicin resistance to E. coli. 45 These analyses reveal significant antibiotic-specific microbial and compositional responses of the preterm infant gut microbiota. For a commonly prescribed antibiotic regimen, co-therapy with vancomycin and gentamicin, Gibson et al. identified important species and antibiotic resistance gene biomarkers that can predict with high accuracy the short-term species richness response and therefore potential for disruption of the developing preterm infant gut microbiota.
Implications for future research
It is evident that use of specific antibiotics in the NICU, such as next generation b-lactam antibiotics, acutely (but perhaps not durably) perturb the gut microbiota while others, such as gentamicin, are less disruptive. Going forward, it is important to understand the enduring effects of antibiotics on the preterm infant gut microbiota and resistome. Recent studies have observed that multidrug resistant clones present in preterm infants in the NICU are absent at 2 y of age, suggesting that the preterm infant gut may recover following discharge to home. 46 On the other hand, resistance genes persist for months or years after antibiotic therapy in adults. [47] [48] [49] Sequence-based characterizations of gut microbiota composition and resistome of preterm infants after they enter the community are needed to fully understand the longitudinal effects of antibiotics on microbiota composition, multidrug resistant organism persistence, and resistance gene carriage. Longitudinal studies also provide the opportunity to correlate dysbioses that originate in the NICU with health outcomes that are manifest later in life. Additionally, it is important to consider the effect of prenatal and intrapartum antibiotics, and prenatal exposure to microbes, on the infant gut microbiota. This is of particular note in preterm infants, 1 in 4 of whom are born to mothers with an intrauterine infection, 50 and in light of the increasing recognition that the uterus is a nonsterile environment. It is necessary to validate the results of this study and others outside of the preterm human infant context. Murine models of antibiotic use have been invaluable in informing microbiome research. Humanized gnotobiotic models in particular have benefited the field greatly. 10, 16, 51 Development of a humanized infant mouse model for preterm antibiotic therapy would allow for testing of clinical antibiotic protocols in a controlled environment in order to discern their relative impacts on the developing gut microbiota. Such analyses would build on the foundation laid by Gibson et al. to provide an evidence-base supporting a personalized medicine approach to antibiotic treatment, wherein antibiotic use in preterm infant populations will be tailored to limit collateral microbiota disruptions and selection for resistance. 
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